Connor K. Sisk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Connor K. Sisk has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Joe Overman
Clearview Dermatology, Arvada, Colorado
2 shared publications- Laci Turner
University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama
2 shared publications - Nabiha Yusuf
Department of Dermatology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
2 shared publications Abby Bs Vollmer
University of Cincinnati College of Medicine, Cincinnati, Ohio
1 shared publication- Changzhen Wang
Department of Geography and the Environment, The University of Alabama, Tuscaloosa, AL
1 shared publication - Joshua S. Richman
Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama
1 shared publication
Latest Publications
- Open Access
Dietary Fiber and Melanoma: Exploring Microbiome-Driven Immune Modulation
Background/Objectives: The gut microbiome influences melanoma biology and response to immune checkpoint inhibitors. Dietary fiber is a key modifiable factor that shapes the microbial composition and metabolite production. This review summarizes mechanistic, preclinical, and clinical evidence describing how fiber and fiber-responsive taxa may affect melanoma immunity and treatment outcomes. Methods: A literature search of MEDLINE, Embase, and Scopus identified studies published within the past five years examining dietary fiber, gut microbiome interactions, immune modulation, or melanoma outcomes. After screening 491 unique records, 49 peer-reviewed mechanistic, preclinical, observational, and interventional studies were synthesized qualitatively in this narrative review. Results: Fiber fermentation produces short-chain fatty acids that regulate dendritic cell activation, T-cell priming, and cytokine signaling. Preclinical melanoma models show that fibers such as inulin and β-glucan enhance IFN-γ-driven antitumor immunity, increase CD8+ infiltration, and improve checkpoint blockade efficacy in a microbiota-dependent manner. In humans, fiber-rich diets and enrichment of taxa such as Bifidobacterium, Faecalibacterium, and Akkermansia are associated with improved PD-1 inhibitor responses, longer progression-free survival, and possible reductions in ICI-related colitis. Although epidemiologic studies suggest no clear association between fiber intake and melanoma incidence, dietary fiber intake appears to correlate strongly with treatment-related outcomes. Conclusions: Dietary fiber represents a potentially safe and plausible adjunct to melanoma immunotherapy. However, study variability and emerging counterevidence highlight the need for controlled trials to clarify causality and define optimal fiber-based interventions.
Open AccessDietary Fiber and Melanoma: Exploring Microbiome-Driven Immune Modulation
Background/Objectives: The gut microbiome influences melanoma biology and response to immune checkpoint inhibitors. Dietary fiber is a key modifiable factor that shapes the microbial composition and metabolite production. This review summarizes mechanistic, preclinical, and clinical evidence describing how fiber and fiber-responsive taxa may affect melanoma immunity and treatment outcomes. Methods: A literature search of MEDLINE, Embase, and Scopus identified studies published within the past five years examining dietary fiber, gut microbiome interactions, immune modulation, or melanoma outcomes. After screening 491 unique records, 49 peer-reviewed mechanistic, preclinical, observational, and interventional studies were synthesized qualitatively in this narrative review. Results: Fiber fermentation produces short-chain fatty acids that regulate dendritic cell activation, T-cell priming, and cytokine signaling. Preclinical melanoma models show that fibers such as inulin and β-glucan enhance IFN-γ-driven antitumor immunity, increase CD8+ infiltration, and improve checkpoint blockade efficacy in a microbiota-dependent manner. In humans, fiber-rich diets and enrichment of taxa such as Bifidobacterium, Faecalibacterium, and Akkermansia are associated with improved PD-1 inhibitor responses, longer progression-free survival, and possible reductions in ICI-related colitis. Although epidemiologic studies suggest no clear association between fiber intake and melanoma incidence, dietary fiber intake appears to correlate strongly with treatment-related outcomes. Conclusions: Dietary fiber represents a potentially safe and plausible adjunct to melanoma immunotherapy. However, study variability and emerging counterevidence highlight the need for controlled trials to clarify causality and define optimal fiber-based interventions.
- Top Cited PapersOpen Access
Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms
Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.
Top Cited PapersOpen AccessAdvances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms
Melanoma remains one of the deadliest cutaneous malignancies worldwide, and despite advances in systemic therapy, recurrence and treatment resistance remain frequent challenges. Following the success of COVID-19 mRNA vaccines, mRNA-based cancer vaccines targeting melanoma antigens have emerged as a promising therapeutic direction. This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines. A comprehensive search of MEDLINE, Embase, and Scopus from 2015 to 2025 identified clinical trials, preclinical studies, and review articles evaluating mRNA vaccine constructs and delivery strategies. Completed clinical studies demonstrate that personalized LNP-formulated mRNA vaccines can enhance neoantigen-specific T-cell responses and improve recurrence-free survival, particularly when combined with immune checkpoint inhibitors. DC-based mRNA vaccines also show potent immunogenicity, with stronger responses observed when DC maturation is optimized. Ongoing trials continue to investigate next-generation LNP formulations, DC priming strategies, and personalized neoantigen approaches. Overall, current evidence indicates that both LNP and DC platforms can augment antitumor immunity by broadening T-cell responses and enhancing checkpoint inhibition. Continued refinement of delivery vehicles, neoantigen selection, and scalable manufacturing processes will be essential to realizing the full clinical potential of mRNA vaccines in melanoma.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500163
Geospatial Analysis of Commission on Cancer-Accredited Centers Within Cancer Care Utilization–Based Catchment Areas
PURPOSE: The Commission on Cancer (CoC) seeks to expand access to high-quality care through community engagement standards targeting centers' catchment areas and efforts to accredit centers in more areas including rural hospitals. Little is known about the social, environmental, and geographic characteristics of their catchment areas. To support future investigation into the impact of CoC-accredited centers, this study compares characteristics of cancer care utilization–based catchment areas, termed Cancer Service Areas ( CSAs ), with and without CoC-accredited centers. METHODS: Geocoded CoC-accredited centers and cancer care patient flows extracted from Medicare claims data were used to delineate CSAs using a spatially constrained community detection method. Characteristics including environmental justice index (EJI), social vulnerability index (SVI), rurality, travel time, and localization index (LI, a ratio of cancer care received by patients within a CSA) were aggregated by CSA. A logistic regression model was created to evaluate characteristics associated with the presence of a CoC-accredited center within a CSA. RESULTS: Six hundred sixty-eight CSAs were defined, of which 511 CSAs had at least one CoC-accredited center. CSAs with CoC-accredited centers had lower health vulnerability (odds ratio [OR], 0.65 [95% CI, 0.427 to 0.993]) and lower racial and ethnic minority status vulnerability (OR, 0.61 [95% CI, 0.424 to 0.886]), but no differences for other components of the EJI or SVI. These CSAs also had higher LIs, meaning patients remained in their local CSA for care (OR, 9.00 [95% CI, 2.408 to 33.640] for high v low LIs). CONCLUSION: Minority and comorbid populations may have more difficulty accessing cancer center care, further exacerbating observed variations in cancer outcomes. Cancer centers may address this by broadening their outreach into at-risk catchment areas.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500163
Geospatial Analysis of Commission on Cancer-Accredited Centers Within Cancer Care Utilization–Based Catchment Areas
PURPOSE: The Commission on Cancer (CoC) seeks to expand access to high-quality care through community engagement standards targeting centers' catchment areas and efforts to accredit centers in more areas including rural hospitals. Little is known about the social, environmental, and geographic characteristics of their catchment areas. To support future investigation into the impact of CoC-accredited centers, this study compares characteristics of cancer care utilization–based catchment areas, termed Cancer Service Areas ( CSAs ), with and without CoC-accredited centers. METHODS: Geocoded CoC-accredited centers and cancer care patient flows extracted from Medicare claims data were used to delineate CSAs using a spatially constrained community detection method. Characteristics including environmental justice index (EJI), social vulnerability index (SVI), rurality, travel time, and localization index (LI, a ratio of cancer care received by patients within a CSA) were aggregated by CSA. A logistic regression model was created to evaluate characteristics associated with the presence of a CoC-accredited center within a CSA. RESULTS: Six hundred sixty-eight CSAs were defined, of which 511 CSAs had at least one CoC-accredited center. CSAs with CoC-accredited centers had lower health vulnerability (odds ratio [OR], 0.65 [95% CI, 0.427 to 0.993]) and lower racial and ethnic minority status vulnerability (OR, 0.61 [95% CI, 0.424 to 0.886]), but no differences for other components of the EJI or SVI. These CSAs also had higher LIs, meaning patients remained in their local CSA for care (OR, 9.00 [95% CI, 2.408 to 33.640] for high v low LIs). CONCLUSION: Minority and comorbid populations may have more difficulty accessing cancer center care, further exacerbating observed variations in cancer outcomes. Cancer centers may address this by broadening their outreach into at-risk catchment areas.
- 20 June 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
Repair of a Large Central Forehead Defect After Mohs Micrographic Surgery
- 20 June 2025
- Published by Wolters Kluwer Health in Dermatologic Surgery
Repair of a Large Central Forehead Defect After Mohs Micrographic Surgery
- 19 December 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (8) , 1469-1470
Repair of a large dorsal mid‐digit defect using a tunneled digital interpolation flap following Mohs micrographic surgery
- 19 December 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (8) , 1469-1470
Repair of a large dorsal mid‐digit defect using a tunneled digital interpolation flap following Mohs micrographic surgery